Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Johnson

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Cancer Research|September 2, 2022
Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Cancer Research|September 2, 2022
Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Carcinogenesis|September 19, 2009
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3Rebecca J Leeman-Neill, Sarah E Wheeler, Shivendra V Singh, et al.
Cancer Research|February 15, 2018
Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2008
Lack of toxicity of a STAT3 decoy oligonucleotideMalabika Sen, Patricia J Tosca, Christa Zwayer, et al.
Cancer Cell|August 29, 2025
Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerJennifer R Grandis, Katherine A Skorupski, Ning Cheng, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
The Journal of Clinical Investigation|November 15, 2021
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinomaNan Jin, Bhumsuk Keam, Janice Cho, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Cancer Discovery|June 22, 2012
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapyMalabika Sen, Sufi M Thomas, Seungwon Kim, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Cancer Research|September 2, 2022
Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Cancer Research|September 2, 2022
Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Carcinogenesis|September 19, 2009
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3Rebecca J Leeman-Neill, Sarah E Wheeler, Shivendra V Singh, et al.
Cancer Research|February 15, 2018
Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck CancerToni M Brand, Stefan Hartmann, Neil E Bhola, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2008
Lack of toxicity of a STAT3 decoy oligonucleotideMalabika Sen, Patricia J Tosca, Christa Zwayer, et al.
Cancer Cell|August 29, 2025
Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerJennifer R Grandis, Katherine A Skorupski, Ning Cheng, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
The Journal of Clinical Investigation|November 15, 2021
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinomaNan Jin, Bhumsuk Keam, Janice Cho, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Cancer Discovery|June 22, 2012
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapyMalabika Sen, Sufi M Thomas, Seungwon Kim, et al.
Pageof 11